IMAC Holdings, Inc. Announces Opening Enrollment in Its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease

Stock Information for Magal Security Systems Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Magal Security Systems Ltd.

IMAC Holdings Expands Florida Presence to Orlando Following Acquisition of Synergy Healthcare
IMAC Holdings Appoints Sheri Gardzina as Secretary, Chief Financial Officer
IMAC Holdings to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
IMAC Holdings Completes First Infusion of Stem Cells in Clinical Study for the Treatment of Bradykinesia Due to Parkinson's Disease
IMAC Holdings Receives Forgiveness of $1.69 Million PPP Loan
IMAC Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
IMAC Holdings, Inc. To Participate in the Virtual Fall Investor Summit on November 16-18, 2020
IMAC Holdings Reports Third Quarter 2020 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.